Can G-CSF cause leukemia in hematopoietic stem cell donors?

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 12, 2011, Pages 1739-1746

  Avalos, Belinda R ^a   Lazaryan, Aleksandr ^b   Copelan, Edward A ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

G CSF; Peripheral blood progenitor cell mobilization; Stem cell donors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; BONE MARROW; BREAST CANCER; DISEASE SEVERITY; DONOR; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; INCIDENCE; LEUKEMIA; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; REVIEW; RISK ASSESSMENT; SOLID TUMOR; STEM CELL MOBILIZATION;

BLOOD SPECIMEN COLLECTION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; TISSUE DONORS;

EID: 81255160680     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.003     Document Type: Review

References (96)

1. Demetri G.D., Griffin J.D. Granulocyte colony-stimulating factor and its receptor. Blood 1991, 78:2791-2808.
2. Williams G.T., Smith C.A., Spooncer E., et al. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990, 343:76-79.
3. Hammond W.P., Chatta G.S., Andrews R.G., et al. Abnormal responsiveness of granulocyte-committed progenitor cells in cyclic neutropenia. Blood 1992, 79:2536-2539.
4. Avalos B.R. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996, 88:761-777.
5. Avalos B.R., Broudy V.C., Ceselski S.K., et al. Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression. Blood 1994, 84:789-794.
6. Begley C.G., Metcalf D., Nicola N.A. Binding characteristics and proliferative action of purified granulocyte colony-stimulating factor (G-CSF) on normal and leukemic human promyelocytes. Exp Hematol 1988, 16:71-79.
7. Avalos B.R., Gasson J.C., Hedvat C., et al. Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 1990, 75:851-857.
8. Hermans M.H., Ward A.C., Antonissen C., et al. Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood 1998, 92:32-39.
9. Liu F., Wu H.Y., Wesselschmidt R., et al. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 1996, 5:491-501.
10. McLemore M.L., Poursine-Laurent J., Link D.C. Increased granulocyte colony-stimulating factor responsiveness but normal resting granulopoiesis in mice carrying a targeted granulocyte colony-stimulating factor receptor mutation derived from a patient with severe congenital neutropenia. J Clin Invest 1998, 102:483-492.
11. Richards M.K., Liu F., Iwasaki H., et al. Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway. Blood 2003, 102:3562-3568.
12. Lieschke G.J., Grail D., Hodgson G., et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994, 84:1737-1746.
13. Dong F., van Paassen M., van Buitenen C., et al. A point mutation in the granulocyte colony stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the overexpression of a novel G-CSF-R isoform. Blood 1995, 85:902.
14. Larsen A., Davis T., Curtis B.M., et al. Expression cloning of a human granulocyte colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains. J Exp Med 1990, 172:1559.
15. Fukunaga R., Seto Y., Mizushima S., Nagata S. Three different mRNAs encoding human granulocyte colony-stimulating factor receptor. Proc Natl Acad Sci U S A 1990, 87:8702-8706.
16. Tweardy D.J., Anderson K., Cannizzaro L.A., et al. Molecular cloning of cDNAs for the human granulocyte colony-stimulating factor receptor from HL-60 cells and mapping of the gene to chromosome region 1p32-34. Blood 1992, 79:1148-1154.
17. Tkatch L.S., Tweardy D.J. Human granulocyte colony-stimulating factor (G-CSF), the premier granulopoietin: biology, clinical utility, and receptor structure and function. Lymphokine Cytokine Res 1993, 12:477-488.
18. White S.M., Ball E.D., Ehman W.C., et al. Increased expression of the differentiation-defective granulocyte colony-stimulating factor receptor mRNA isoform in acute myelogenous leukemia. Leukemia 1998, 12:899-906.
19. Crawford J., Ozer H., Stoller R., et al. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325:164-170.
20. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994, 12:2471-2508. American Society of Clinical Oncology.
21. Ozer H., Miller L.L., Schiffer C.A., et al. American Society of Clinical Oncology update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996, 14:1957-1960.
22. Ozer H., Armitage J.O., Bennett C.L., et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000, 18:3558-3585.
23. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
24. Dong F., Brynes R.K., Tidow N., et al. Mutations in the gene for the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995, 333:487-493.
25. Hunter M.G., Avalos B.R. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood 1999, 93:440-446.
26. Hunter M.G., Avalos B.R. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. Blood 2000, 95:2132-2137.
27. Hermans M.H., Ward A.C., Antonissen C. Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood 1998, 92:32-39.
28. McLemore M.L., Poursine-Laurent J., Link D.C. Increased granulocyte colony-stimulating factor responsiveness but normal resting granulopoiesis in mice carrying a targeted granulocyte colony-stimulating factor receptor mutation derived from a patient with severe congenital neutropenia. J Clin Invest 1998, 102:483-492.
29. Link D.C., Kunter G., Kasai Y., et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood 2007, 110:1648-1655.
30. Germeshausen M., Ballmaier M., Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood 2007, 109:93-99.
31. van de Geijn G.J., Aarts L.H., Erkeland S.J., et al. Granulocyte colony-stimulating factor and its receptor in normal hematopoietic cell development and myeloid disease. Rev Physiol Biochem Pharmacol 2003, 149:53-71.
32. Touw I.P., Bontenbal M. Granulocyte colony-stimulating factor: key factor or innocent bystander in the development of secondary myeloid malignancy?. J Natl Cancer Inst 2007, 99:183-186.
33. Rosenberg P.S., Alter B.P., Bolyard A.A., et al. Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006, 107:4628-4635.
34. Dale D.C., Cottle T.E., Fier C.J., et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003, 72:82-93.
35. Freedman M.H., Bonilla M.A., Fier C., et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000, 96:429-436.
36. Cannistra S.A., Groshek P., Griffin J.D. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989, 3:328-334.
37. Vellenga E., Young D.C., Wagner K., et al. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987, 69:1771-1776.
38. Cannistra S.A., DiCarlo J., Groshek P., et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991, 5:230-238.
39. Frenette P.S., Desforges J.F., Schenkein D.P., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia. Am J Hematol 1995, 49:48-55.
40. Rowe J.M., Neuberg D., Friedenberg W., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004, 103:479-485.
41. Witz F., Sadoun A., Perrin M.C., et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998, 91:2722-2730.
42. Lowenberg B., van Putten W., Theobald M., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003, 349:743-752.
43. Thomas X., Raffoux E., Botton S., et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (AFLA) Group. Leukemia 2007, 21:453-461.
44. Heil G., Chadid L., Hoelzer D., et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995, 9:3-9.
45. Ehlers S., Herbst C., Zimmerman M., et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 2010, 28:2591-2597.
46. Relling M.V., Boyett J.M., Blanco J.G., et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003, 101:3862-3867.
47. Krishnan A., Bhatia S., Slovak M.L., et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000, 95:1588-1593.
48. Socolovsky M., Fallon A.E., Wang S., et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/-mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999, 98:181-191.
49. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006, 354:2034-2045.
50. Lyman G.H., Dale D.C., Wolff D.A., et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systemic review. J Clin Oncol 2010, 28:2914-2924.
51. Smith R.E., Bryant J., DeCillis A., Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003, 21:1195-1204.
52. Kaushansky K. Lineage specific hematopoietic growth factors. N Engl J Med 2006, 355:526-527. (author reply 527).
53. Socie G., Mary J.Y., Schrezenmeier H., et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007, 109:2794-2796.
54. Kojima S., Ohara A., Tsuchida M., et al. Risk factors for evolution if acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002, 100:786-790.
55. Sloand E.M., Yong A.S., Ramkissoon S., et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monsomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A 2006, 103:14483-14488.
56. Christopher M.J., Rao M., Liu F., et al. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 2011, 208:251-260.
57. Nervi B., Link D.C., DiPersio J.F. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006, 99:690-705.
58. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000, 95:3702-3709.
59. Powles R., Mehta J., Kulkarni S., et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000, 355:1231-1237.
60. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
61. Powles R. 50 years of allogeneic bone-marrow transplantation. Lancet Oncol 2010, 11:305-306.
62. Stem Cell Donor Registries Annual Report 2008 2008, World Marrow Donor Association Donor Registries Working Group, World Marrow Donor Association, Leiden. 12th ed.
63. Friedrichs B., Tichelli A., Bacigalupo A., et al. Long-term outcome and late effects in patients transplanted with mobilized blood or bone marrow: a randomised trial. Lancet Oncol 2010, 11:331-338.
64. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010, 11:653-660.
65. Pidala J., Anasetti C., Kharfan-Dabaja M.A., Cutler C., et al. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:1415-1421.
66. Stroncek D.F., Holland P.V., Bartch G., et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood 1993, 81:1940-1946.
67. Pulsipher M.A., Chitphakdithai P., Miller J.P., et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009, 113:3604-3611.
68. Holig K., Kramer M., Kroschinsky F., et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009, 114:3757-3763.
69. Tigue C.C., McKoy J.M., Evens A.M., et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007, 40:185-192.
70. Schmidt A.H., Mengling T., Pingel J., et al. Follow-up of 12,559 unrelated donors of peripheral blood stem cells or bone marrow. Blood (ASH Annu Meet Abstr) 2010, 116. Abstract 365.
71. Pulsipher M.A., Chitphakdithai P., Logan B.R., et al. Peripheral blood stem cell (PBSC) donors experience higher levels of pain and toxicities early on, while bone marrow (BM) donors experience slower recovery and more late pain: a prospective study of the National Marrow Donor Program (NMDP). Blood (ASH Annu Meet Abstr) 2010, 116. Abstract 1107.
72. Switzer G.E., Harrington B.A., Haagenson M.D., et al. Health-related quality of life among adult matched unrelated stem cell donors: a Blood and Marrow Transplant Clinical Trials Network (BMT CTN) randomized trial of marrow versus PBSC donation. Blood (ASH Annu Meet Abstrs) 2010, 116. Abstract 366.
73. Bennett C.L., Evens A.M., Andritsos L.A., et al. Hematologic malignancies developing in previously healthy individuals who received hematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006, 135:642-650.
74. Makita K., Ohta K., Mugitani A., et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004, 33:661-665.
75. Oransky I. A waiting trial. Scientist 2008, 22:44-79.
76. Sakamaki S., Matsunaga T., Hirayama Y., et al. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995, 346:1432-1433.
77. Cavallaro A.M., Lilleby K., Majolino I., et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000, 25:85-89.
78. Pulsipher M.A., Levine J.E., Hayashi R.J., et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PNMTC) 1996-2003. Bone Marrow Transplant 2005, 35:361-367.
79. Horowitz M.M., Confer D.L. Evaluation of hematopoietic stem cell donors. The American Society of Hematology. Hematology 2005, 469-475.
80. Anderlini P., Chan F.A., Champlin R.E., et al. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 2002, 30:661-663.
81. Tassi C., Tazzari P.L., Bonifazi F., et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005, 36:289-294.
82. Confer D.L., Miller J.P. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007, 137:77-78. (author reply 79-80).
83. de la Rubia J., de Arriba F., Arbona C., et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008, 93:735-740.
84. Halter J., Kodera Y., Ispizua A.U., et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009, 94:94-101.
85. Hasenclever D., Sextro M. Safety of alloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996, 17(Suppl 2):S28-S30.
86. Anderlini P. Donors, donors, and more donors. Blood 2009, 18:3721-3722.
87. Confer DL, Shaw BE, Pamphilon DH. WMDA guidelines for subsequent donations following initial BM or PBSCs. Bone Marrow Transplantation advanced online publication 7 February 2011; doi:10.1038/bmt.2010.323.
88. Hernandez J.M., Castilla C., Gutierrez N.C., et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005, 19:1088-1091.
89. Kaplinsky C., Trakhtenbrot L., Hardan I., et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003, 32:31-34.
90. Nagler A., Korenstein-Ilan A., Amiel A., Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004, 32:122-130.
91. Robinet Eric G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division. Blood 2010, 28:910-911.
92. Rondelli D., Raspadori D., Anasetti C., et al. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 1998, 22:631-637.
93. Su Y.C., Hsu C.K., Yu C.C., et al. G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT. Bone Marrow Transplant 2011 Feb 28, [Epub ahead of print].
94. Anderlini P., Champlin R.E. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008, 111:1767-1772.
95. Shaw B.E., Ball L., Bengtsson M., et al. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transplant 2010, 45:832-838.
96. Pulsipher M.A., Nagler A., Iannone R., Nelson R.M. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006, 46:422-433.